{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:03:58Z","timestamp":1794891838105,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T00:00:00Z","timestamp":1526601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombotic thrombocytopenic purpura (TTP) is primarily caused by deficiency of ADAMTS13 within the blood stream due to either genetic defects or presence of inhibitory autoantibodies. Preclinical and clinical studies suggest that enzyme replacement therapy with recombinant human ADAMTS13 protein (rhADAMTS13) is effective and safe in treatment of TTP. However, frequent dosing would be required due to the relatively short half-life of rhADAMTS13 in circulation as well as the presence of inhibitory autoantibodies that collectively result in the poor pharmacological profile of rhADAMTS13. With technical breakthroughs in exploring mRNA as therapeutics, we hypothesized that restoration of ADAMTS13 activity for a prolonged duration of time can be achieved through systemic dosing of mRNA, wherein the dosed mRNA would utilize hepatic cells as bioreactors for continuous production of ADAMTS13. To test this hypothesis, mRNA encoding human ADAMTS13 WT or an ADAMTS13 variant, that had demonstrated resistance to predominant clinical TTP autoantibodies, was formulated in lipid nano-particles for liver-targeted delivery. In both ADAMTS13-sufficient and -deficient mice, a single dose of the formulated mRNAs at 1\u2009mg\/kg resulted in expression of hADAMTS13 at or above therapeutically relevant levels in mice for up to five days. This proof-of-concept study suggests that mRNA therapy could provide a novel approach for TTP treatment.<\/jats:p>","DOI":"10.1038\/s41598-018-26298-4","type":"journal-article","created":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T10:23:29Z","timestamp":1526293409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice"],"prefix":"10.1038","volume":"8","author":[{"given":"Susan","family":"Liu-Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-9895","authenticated-orcid":false,"given":"Romesh R.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,18]]},"reference":[{"key":"26298_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1056\/NEJMcp053024","volume":"354","author":"JN George","year":"2006","unstructured":"George, J. N. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 354, 1927\u20131935 (2006).","journal-title":"Thrombotic thrombocytopenic purpura. N Engl J Med."},{"key":"26298_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s11239-016-1395-7","volume":"42","author":"G Berti de Marinis","year":"2016","unstructured":"Berti de Marinis, G. et al. Correlation between adamts13 activity and neurological impairment in acute thrombotic microangiopathy patients. J Thromb Thrombolysis. 42, 586\u2013592 (2016).","journal-title":"J Thromb Thrombolysis."},{"key":"26298_CR3","doi-asserted-by":"publisher","first-page":"11902","DOI":"10.1073\/pnas.172277399","volume":"99","author":"K Kokame","year":"2002","unstructured":"Kokame, K. et al. Mutations and common polymorphisms in adamts13 gene responsible for von willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 99, 11902\u201311907 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"26298_CR4","doi-asserted-by":"publisher","first-page":"31493","DOI":"10.1074\/jbc.R109.052340","volume":"284","author":"SS Apte","year":"2009","unstructured":"Apte, S. S. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (adamts) superfamily: Functions and mechanisms. J Biol Chem. 284, 31493\u201331497 (2009).","journal-title":"J Biol Chem."},{"key":"26298_CR5","doi-asserted-by":"publisher","first-page":"41059","DOI":"10.1074\/jbc.C100515200","volume":"276","author":"X Zheng","year":"2001","unstructured":"Zheng, X. et al. Structure of von willebrand factor-cleaving protease (adamts13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 276, 41059\u201341063 (2001).","journal-title":"J Biol Chem."},{"key":"26298_CR6","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","volume":"119","author":"A Schiviz","year":"2012","unstructured":"Schiviz, A. et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: Correction of symptoms by recombinant human adamts13. Blood. 119, 6128\u20136135 (2012).","journal-title":"Blood."},{"key":"26298_CR7","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ajh.24559","volume":"91","author":"Y Benhamou","year":"2016","unstructured":"Benhamou, Y. et al. Efficacy of a rituximab regimen based on b cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase ii, multicenter noncomparative study. Am J Hematol. 91, 1246\u20131251 (2016).","journal-title":"Am J Hematol."},{"key":"26298_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ajh.23106","volume":"87","author":"SR Cataland","year":"2012","unstructured":"Cataland, S. R. et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of arc1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 87, 430\u2013432 (2012).","journal-title":"Am J Hematol."},{"key":"26298_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1365-2141.2012.09084.x","volume":"157","author":"J Chapin","year":"2012","unstructured":"Chapin, J., Weksler, B., Magro, C. & Laurence, J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 157, 772\u2013774 (2012).","journal-title":"Br J Haematol."},{"key":"26298_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1172\/JCI41062","volume":"121","author":"J Chen","year":"2011","unstructured":"Chen, J. et al. N-acetylcysteine reduces the size and activity of von willebrand factor in human plasma and mice. J Clin Invest. 121, 593\u2013603 (2011).","journal-title":"J Clin Invest."},{"issue":"3825\u20133829","key":"26298_CR11","first-page":"S3821","volume":"121","author":"SY Jin","year":"2013","unstructured":"Jin, S. Y. et al. AAV-mediated expression of an Adamts13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood. 121(3825\u20133829), S3821\u20133823 (2013).","journal-title":"Blood."},{"key":"26298_CR12","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.12696","volume":"164","author":"MA Mazepa","year":"2014","unstructured":"Mazepa, M. A., Raval, J. S., Moll, S., Ma, A. & Park, Y. A. Bortezomib induces clinical remission and reduction of adamts13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 164, 900\u2013902 (2014).","journal-title":"Br J Haematol."},{"key":"26298_CR13","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 374, 511\u2013522 (2016).","journal-title":"N Engl J Med."},{"key":"26298_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1161\/ATVBAHA.116.308680","volume":"37","author":"S Verhenne","year":"2017","unstructured":"Verhenne, S. et al. Long-term prevention of congenital thrombotic thrombocytopenic purpura in adamts13 knockout mice by sleeping beauty transposon-mediated gene therapy. Arterioscler Thromb Vasc Biol. 37, 836\u2013844 (2017).","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"26298_CR15","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","volume":"9","author":"B Plaimauer","year":"2011","unstructured":"Plaimauer, B. et al. Recombinant adamts13 normalizes von willebrand factor-cleaving activity in plasma of acquired ttp patients by overriding inhibitory antibodies. J Thromb Haemost. 9, 936\u2013944 (2011).","journal-title":"J Thromb Haemost."},{"key":"26298_CR16","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1182\/blood-2012-06-439935","volume":"120","author":"SF De Meyer","year":"2012","unstructured":"De Meyer, S. F. et al. Protective anti-inflammatory effect of adamts13 on myocardial ischemia\/reperfusion injury in mice. Blood. 120, 5217\u20135223 (2012).","journal-title":"Blood."},{"key":"26298_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1055\/s-0037-1614408","volume":"81","author":"M Furlan","year":"1999","unstructured":"Furlan, M., Robles, R., Morselli, B., Sandoz, P. & Lammle, B. Recovery and half-life of von willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 81, 8\u201313 (1999).","journal-title":"Thromb Haemost."},{"key":"26298_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jth.12494","volume":"12","author":"LA Lotta","year":"2014","unstructured":"Lotta, L. A. et al. Measurement and prevalence of circulating adamts13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost. 12, 329\u2013336 (2014).","journal-title":"J Thromb Haemost."},{"key":"26298_CR19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3324\/haematol.2013.094151","volume":"99","author":"S Ferrari","year":"2014","unstructured":"Ferrari, S. et al. Persistence of circulating adamts13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica. 99, 779\u2013787 (2014).","journal-title":"Haematologica."},{"key":"26298_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/nbt.2682","volume":"31","author":"L Zangi","year":"2013","unstructured":"Zangi, L. et al. Modified mrna directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol. 31, 898\u2013907 (2013).","journal-title":"Nat Biotechnol."},{"key":"26298_CR21","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","volume":"119","author":"C Jian","year":"2012","unstructured":"Jian, C. et al. Gain-of-function adamts13 variants that are resistant to autoantibodies against adamts13 in patients with acquired thrombotic thrombocytopenic purpura. Blood. 119, 3836\u20133843 (2012).","journal-title":"Blood."},{"key":"26298_CR22","doi-asserted-by":"publisher","first-page":"E1941","DOI":"10.1073\/pnas.1619653114","volume":"114","author":"S Ramaswamy","year":"2017","unstructured":"Ramaswamy, S. et al. Systemic delivery of factor ix messenger rna for protein replacement therapy. Proc Natl Acad Sci USA 114, E1941\u2013E1950 (2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"26298_CR23","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","volume":"124","author":"M Schaller","year":"2014","unstructured":"Schaller, M., Vogel, M., Kentouche, K., Lammle, B. & Kremer Hovinga, J. A. The splenic autoimmune response to adamts13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding cdr3 motifs. Blood. 124, 3469\u20133479 (2014).","journal-title":"Blood."},{"key":"26298_CR24","doi-asserted-by":"publisher","first-page":"39934","DOI":"10.1074\/jbc.M504919200","volume":"280","author":"W Zhou","year":"2005","unstructured":"Zhou, W., Dong, L., Ginsburg, D., Bouhassira, E. E. & Tsai, H. M. Enzymatically active adamts13 variants are not inhibited by anti-adamts13 autoantibodies: A novel therapeutic strategy? J Biol Chem. 280, 39934\u201339941 (2005).","journal-title":"J Biol Chem."},{"key":"26298_CR25","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1182\/blood-2014-07-587139","volume":"125","author":"B Pickens","year":"2015","unstructured":"Pickens, B. et al. Platelet-delivered adamts13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood. 125, 3326\u20133334 (2015).","journal-title":"Blood."},{"key":"26298_CR26","doi-asserted-by":"publisher","first-page":"30925","DOI":"10.1074\/jbc.M109.000927","volume":"284","author":"AN Vomund","year":"2009","unstructured":"Vomund, A. N. & Majerus, E. M. Adamts13 bound to endothelial cells exhibits enhanced cleavage of von willebrand factor. J Biol Chem. 284, 30925\u201330932 (2009).","journal-title":"J Biol Chem."},{"key":"26298_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries, O. et al. N(1)-methylpseudouridine-incorporated mrna outperforms pseudouridine-incorporated mrna by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 217, 337\u2013344 (2015).","journal-title":"J Control Release."},{"key":"26298_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jconrel.2017.01.045","volume":"249","author":"M Utzinger","year":"2017","unstructured":"Utzinger, M. et al. Cmrna\/lipoplex encapsulation in plga microspheres enables transfection via calcium phosphate cement (cpc)\/plga composites. J Control Release. 249, 143\u2013149 (2017).","journal-title":"J Control Release."},{"key":"26298_CR29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","volume":"217","author":"N Pardi","year":"2015","unstructured":"Pardi, N. et al. Expression kinetics of nucleoside-modified mrna delivered in lipid nanoparticles to mice by various routes. J Control Release. 217, 345\u2013351 (2015).","journal-title":"J Control Release."},{"key":"26298_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.omtn.2017.04.006","volume":"7","author":"E Schrom","year":"2017","unstructured":"Schrom, E. et al. Translation of angiotensin-converting enzyme 2 upon liver- and lung-targeted delivery of optimized chemically modified mrna. Mol Ther Nucleic Acids. 7, 350\u2013365 (2017).","journal-title":"Mol Ther Nucleic Acids."},{"key":"26298_CR31","doi-asserted-by":"publisher","unstructured":"Asrani, K. H. et al. Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biology, https:\/\/doi.org\/10.1080\/15476286.2018.1450054 (2018).","DOI":"10.1080\/15476286.2018.1450054"},{"key":"26298_CR32","doi-asserted-by":"publisher","unstructured":"Farelli, J. D. et al. Leveraging rational protein engineering to improve mRNA therapeutics. Nucleic Acid Therapeutics. 28(2), https:\/\/doi.org\/10.1089\/nat.2017.0697 (2018).","DOI":"10.1089\/nat.2017.0697"},{"issue":"6","key":"26298_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mrna vaccines protect against zika virus infection. Cell. 168(6), 1114\u20131125e10 (2017).","journal-title":"Cell."},{"key":"26298_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14630","volume":"8","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Administration of nucleoside-modified mrna encoding broadly neutralizing antibody protects humanized mice from hiv-1 challenge. Nat Commun. 8, 14630, https:\/\/doi.org\/10.1038\/ncomms14630 (2017).","journal-title":"Nat Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26298-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26298-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:30:12Z","timestamp":1671582612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-26298-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,18]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["26298"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-26298-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,18]]},"assertion":[{"value":"15 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are salaried employees at Alexion Pharmaceuticals Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7859"}}